Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials
Authors: Shinkan Tokudome, Ryosuke Ando, Shuji Hashimoto
Journal: Annals of Internal Medicine (2018)

Letters17 April 2018Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO TrialsShinkan Tokudome, MD, Ryosuke Ando, MD, and Shuji Hashimoto, PhDShinkan Tokudome, MDLaboratory of Cancer Epidemiology and Prevention, Nisshin, Japan (S.T.)Search for more papers by this author, Ryosuke Ando, MDNagoya City University Graduate School of Medical Sciences, Nagoya, Japan (R.A.)Search for more papers by this author, and Shuji Hashimoto, PhDFujita Health University School of Medicine, Toyoake, Japan (S.H.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0737 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Tsodikov and colleagues (1) seem to have resolved a long-standing controversy about the effectiveness of PSA-based screening for mortality reduction in prostate cancer—namely, the discrepancy between the ERSPC (2) and PLCO (3). They did so by applying the same analysis method (Cox regression analysis) to MLTs. Screening translated to an estimated prostate cancer mortality reduction between 25% and 31% in the ERSPC population and 27% and 32% in the PLCO population compared with no screening.Insufficient statistical power of the ERSPC was salvaged by extending the observation period to 11 years to increase the number of deaths ...References1. Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;167:449-55. [PMID: 28869989]. doi:10.7326/M16-2586 LinkGoogle Scholar2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8. [PMID: 19297566] doi:10.1056/NEJMoa0810084 CrossrefMedlineGoogle Scholar3. Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9. [PMID: 19297565] doi:10.1056/NEJMoa0810696 CrossrefMedlineGoogle Scholar4. Bibbins-Domingo K, Grossman DC, Curry SJ. The US Preventive Services Task Force 2017 draft recommendation statement on screening for prostate cancer: an invitation to review and comment. JAMA. 2017;317:1949-50. [PMID: 28397958] doi:10.1001/jama.2017.4413 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Laboratory of Cancer Epidemiology and Prevention, Nisshin, Japan (S.T.)Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan (R.A.)Fujita Health University School of Medicine, Toyoake, Japan (S.H.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0737. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Alex Tsodikov , Roman Gulati , Eveline A.M. Heijnsdijk , Paul F. Pinsky , Sue M. Moss , Sheng Qiu , Tiago M. de Carvalho , Jonas Hugosson , Christine D. Berg , Anssi Auvinen , Gerald L. Andriole , Monique J. Roobol , E. David Crawford , Vera Nelen , Maciej Kwiatkowski , Marco Zappa , Marcos Luján , Arnauld Villers , Eric J. Feuer , Harry J. de Koning , Angela B. Mariotto , and Ruth Etzioni Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Alex Tsodikov , Roman Gulati , and Ruth Etzioni Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Philippe Autier and Peter Boyle Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Join Y. Luh , Steven E. Finkelstein , Jeff M. Michalski , and Howard Sandler MD Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Stuart G. Baker Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials Philip C. Prorok and Anthony B. Miller Metrics 17 April 2018Volume 168, Issue 8Page: 608KeywordsCancer screeningConflicts of interestDisclosureElderlyMortalityProstate cancerRegression analysisSurvival analysis ePublished: 17 April 2018 Issue Published: 17 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...